[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE269295T1 - Btk inhibitoren und verfahren zur identifizierung und verwendung - Google Patents

Btk inhibitoren und verfahren zur identifizierung und verwendung

Info

Publication number
ATE269295T1
ATE269295T1 AT99918673T AT99918673T ATE269295T1 AT E269295 T1 ATE269295 T1 AT E269295T1 AT 99918673 T AT99918673 T AT 99918673T AT 99918673 T AT99918673 T AT 99918673T AT E269295 T1 ATE269295 T1 AT E269295T1
Authority
AT
Austria
Prior art keywords
identification
methods
btk inhibitors
inhibitors
btk
Prior art date
Application number
AT99918673T
Other languages
English (en)
Inventor
Fatih M Uckun
Yaguo Zheng
Sutapa Ghosh
Original Assignee
Parker Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/273,191 external-priority patent/US6303652B1/en
Application filed by Parker Hughes Inst filed Critical Parker Hughes Inst
Application granted granted Critical
Publication of ATE269295T1 publication Critical patent/ATE269295T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
AT99918673T 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung ATE269295T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8209498P 1998-04-17 1998-04-17
US09/273,191 US6303652B1 (en) 1998-08-21 1999-03-19 BTK inhibitors and methods for their identification and use
PCT/US1999/008556 WO1999054286A2 (en) 1998-04-17 1999-04-19 Btk inhibitors and methods for their identification and use

Publications (1)

Publication Number Publication Date
ATE269295T1 true ATE269295T1 (de) 2004-07-15

Family

ID=26767041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918673T ATE269295T1 (de) 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung

Country Status (13)

Country Link
EP (1) EP1071658B1 (de)
JP (1) JP2002512216A (de)
KR (1) KR20010042804A (de)
AT (1) ATE269295T1 (de)
AU (1) AU3653099A (de)
CA (1) CA2328962A1 (de)
DE (1) DE69918089T2 (de)
ES (1) ES2222705T3 (de)
HU (1) HUP0102661A2 (de)
IL (1) IL139080A0 (de)
MX (1) MXPA00010150A (de)
NO (1) NO20005224L (de)
WO (1) WO1999054286A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6306897B1 (en) * 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
JP2003513967A (ja) 1999-11-05 2003-04-15 サイトビア インコーポレイテッド カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換４ｈクロメンおよびアナログ、ならびにその使用
AU4508601A (en) * 1999-11-30 2001-06-18 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2001236361A1 (en) * 2000-10-20 2002-05-06 Parker Hughes Institute Treatment of asthma with lfm analogues
AU2002236692A1 (en) * 2000-10-23 2002-05-21 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use
AU2002306618B2 (en) * 2001-03-07 2006-11-09 Telik, Inc. Substituted diarylureas as stimulators for Fas-mediated apoptosis
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
JP4382354B2 (ja) * 2001-03-13 2009-12-09 ヴァルブルク・グリコムド・ゲーエムベーハー １−ブタン酸誘導体およびその使用
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092594A1 (en) 2001-05-16 2002-11-21 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1392283A4 (de) 2001-05-16 2004-10-20 Cytovia Inc Substituierte cumarine und chinoline als caspase-aktivatoren
WO2003027276A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
WO2003096982A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN100349887C (zh) 2002-05-16 2007-11-21 西托维亚公司 取代的4－芳基－4h－吡咯并[2,3－h]色烯和类似物及其药物组合物和用途
AU2003258454A1 (en) 2002-09-06 2004-04-30 Schebo®Biotech Ag Compounds for modulating the glycolosis enzyme complex and/or transaminase complex
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
EP1804782A1 (de) * 2004-10-19 2007-07-11 Aventis Pharmaceuticals Inc. Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung entzündlicher darmerkrankungen
EP2270200A3 (de) * 2006-09-11 2011-07-13 CGI Pharmaceuticals, Inc. Kinasehemmer und Verfahren zur Verwendung und Identifizierung von Kinasehemmern
SI2529622T1 (en) 2006-09-22 2018-06-29 Pharmacyclics Llc Bruton tyrosine kinase inhibitors
PL2134374T3 (pl) * 2007-03-14 2014-11-28 Bionsil S R L In Liquidazione Inhibitory btk w chemoterapeutycznym leczeniu nowotworów nabłonka
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
SG185330A1 (en) * 2007-10-23 2012-11-29 Hoffmann La Roche Novel kinase inhibitors
JP5479105B2 (ja) * 2007-11-05 2014-04-23 国立大学法人佐賀大学 新規ユビキリン結合性小分子
CA2724861A1 (en) 2008-06-05 2009-12-10 Alembic Limited A process for preparing teriflunomide
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EP3409276B1 (de) 2010-04-05 2020-12-30 Fosun Orinove Pharmatech, Inc. Ire-1a-inhibitoren
BR112012030625A2 (pt) 2010-06-03 2017-06-27 Pharmacyclics Inc uso de inibidores de tirosina quinase de bruton (btk)
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
US9540382B2 (en) 2012-06-04 2017-01-10 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
WO2014085308A1 (en) * 2012-11-28 2014-06-05 Corning Incorporated Cell culture medium for enhanced hepatocyte function
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CN105142640B (zh) * 2013-04-02 2017-08-29 豪夫迈·罗氏有限公司 酪氨酸蛋白激酶抑制剂
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
EP2832358A1 (de) * 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmazeutisches Kit zur Verwendung bei der Behandlung von Darm- und kolorektalem Krebs
EP3033079B1 (de) 2013-08-12 2018-10-31 Pharmacyclics LLC Verfahren zur behandlung von her2-verstärktem krebs
TN2016000094A1 (en) 2013-09-30 2017-07-05 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase.
EP3079682A4 (de) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Verfahren zur behandlung eines lymphoplasmazytischen lymphoms
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP3193877A4 (de) 2014-08-07 2018-04-04 Pharmacyclics LLC Neuartige formen eines bruton-tyrosinkinase-hemmers
AU2015335788B2 (en) 2014-10-22 2020-07-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
AU2017240609B2 (en) 2016-03-31 2021-07-15 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555685A1 (de) * 1975-12-11 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
HU222234B1 (hu) * 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
AU5958394A (en) * 1992-12-23 1994-07-19 Smithkline Beecham Corporation Coumarin derivatives as retroviral inhibitors
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5489697A (en) * 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
IT1289238B1 (it) * 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina

Also Published As

Publication number Publication date
JP2002512216A (ja) 2002-04-23
DE69918089T2 (de) 2005-07-14
IL139080A0 (en) 2001-11-25
NO20005224D0 (no) 2000-10-17
DE69918089D1 (de) 2004-07-22
EP1071658B1 (de) 2004-06-16
HUP0102661A2 (hu) 2001-11-28
KR20010042804A (ko) 2001-05-25
EP1071658A2 (de) 2001-01-31
AU3653099A (en) 1999-11-08
MXPA00010150A (es) 2002-05-14
WO1999054286A3 (en) 2000-05-04
NO20005224L (no) 2000-12-18
CA2328962A1 (en) 1999-10-28
WO1999054286A2 (en) 1999-10-28
ES2222705T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE60007095D1 (de) Calanolide zur hemmung von btk
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE553086T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung der multipler medikamentenresistenz
DE60142410D1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
DE60023870D1 (de) Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte
ATE449186T1 (de) Zusammensetzungen und verfahren zur selektiven nukleinsäureisolierung
DK1098649T3 (da) Fremgangsmåde til stabilisering af farmaceutiske sammensætninger med speciel anvendelse af antioxidant
DE60309647D1 (de) System und Verfahren zur gesicherten Behandlung von Kontrollinformationen
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE602004032465D1 (de) Referenzstandard zur charakterisierung von rosuvastatin
DE60315575D1 (de) Verfahren und Vorrichtung zur Untersuchung von Oberflächen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60136607D1 (de) System und Verfahren zur Lieferung von Karteninformationen
DE69838324D1 (de) Ph-sensitive liposomen und andere typen immunomodulatoren enthaltender gekapselter impfstoffe sowie herstellungs- und anwendungsverfahren dafür
NO20033921L (no) Inhibitor av monoaminopptak
DE69941317D1 (de) Verfahren zur Untersuchung von Gasen
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
DE69930844D1 (de) Inhibitoren von mycobakterien
ATE332970T1 (de) Verfahren und zusammensetzungen zur hemmung von neoplastischem zellwachstums
DE50200757D1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
ATE531690T1 (de) Inhibitoren von peptiddeformylase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties